PB-722

PB-722 is a long-acting, PEGylated glucagon receptor agonist developed by PegBio. It is designed as a once-weekly injectable therapy for metabolic diseases such as obesity and congenital hyperinsulinism. The drug acts primarily by stimulating the glucagon receptor (GCGR), which can increase energy expenditure and promote weight loss. In some contexts, it has also been described in combination with exenatide or as part of dual GLP-1/glucagon receptor agonist therapies; however, PB-722 itself is specifically characterized as a glucagon receptor agonist rather than a dual agonist[1][2][3]. Its PEGylation extends its half-life and reduces dosing frequency compared to non-modified peptides[6]. Clinical trials have reached Phase 1/2 for obesity in China and IND approval for congenital hyperinsulinism[2][3].